Fluoxetine: Clinical Guide for Prescribing
Primary Indications
Fluoxetine is FDA-approved for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and bulimia nervosa, with specific dosing protocols for each indication 1. It is the only SSRI officially approved for moderate to severe depression in adolescents aged 8-18 years 2.
Approved Indications by Condition:
Major Depressive Disorder:
- Adults: 20 mg/day in the morning is the recommended starting and maintenance dose 1. Doses of 20 mg/day are sufficient for most patients, though increases up to 80 mg/day maximum may be considered after several weeks if response is inadequate 1.
- Pediatric (8-18 years): Start with 10-20 mg/day. If starting at 10 mg/day, increase to 20 mg/day after 1 week. Lower weight children should target 10 mg/day initially, with increases to 20 mg/day considered after several weeks 1.
Obsessive-Compulsive Disorder:
- Adults: Start at 20 mg/day in the morning. Dose range of 20-60 mg/day is recommended, with maximum of 80 mg/day. Full therapeutic effect may require 5 weeks or longer 1.
- Adolescents and higher weight children: Start 10 mg/day, increase to 20 mg/day after 2 weeks. Target range 20-60 mg/day 1.
- Lower weight children: Start 10 mg/day, target range 20-30 mg/day 1.
Bulimia Nervosa:
- Adults only: 60 mg/day administered in the morning is the recommended dose (titrate up over several days if needed). This is the only dose proven superior to placebo 1.
Contraindications
Absolute contraindications:
- Concurrent use with MAOIs or within 14 days of MAOI discontinuation 1
- At least 5 weeks (potentially longer) must elapse after stopping fluoxetine before starting an MAOI, due to fluoxetine's long half-life 1
Key Prescribing Considerations
Advantages Over Other Antidepressants:
Fluoxetine should be considered preferentially when you want to avoid:
- Anticholinergic effects
- Sedation
- Weight gain (fluoxetine commonly causes weight loss) 3
- Withdrawal symptoms upon discontinuation (long half-life provides natural tapering) 3
Recent meta-analyses demonstrate fluoxetine reduces body weight by approximately 2.1 kg, particularly at doses ≥60 mg/day and in trials ≤12 weeks 4.
Important Caveats:
Avoid fluoxetine in elderly patients - paroxetine and fluoxetine should generally be avoided in older adults due to higher rates of adverse effects 5. Preferred agents for elderly include citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, and bupropion 5.
Panic disorder patients require special dosing: 28% of patients cannot tolerate the standard 20 mg dose 6. For patients with comorbid panic disorder, start at 5 mg/day and titrate slowly to 20 mg over 1 week. Half of those intolerant to 20 mg will respond to lower doses (5-15 mg/day) 6.
Dosing Adjustments for Special Populations
Hepatic impairment: Use lower or less frequent dosing 1
Renal impairment: Dosage adjustments not routinely necessary 1
Elderly: Lower or less frequent dosing recommended 1
Multiple medications or concurrent disease: Consider lower or less frequent dosing 1
Treatment Duration
First episode of major depression: Minimum 4 months of treatment 5
Recurrent depression: Prolonged treatment is beneficial 5
Maintenance therapy: Efficacy demonstrated for up to 38 weeks following 12 weeks of acute treatment (50 weeks total) at 20 mg/day 1. For OCD, continuation beyond 13 weeks is reasonable given the chronic nature of the condition 1.
Monitoring Recommendations
Common Adverse Effects (63% experience at least one):
- Nausea and vomiting (most common reason for discontinuation) 5
- Diarrhea, dizziness, dry mouth, fatigue, headache
- Sexual dysfunction, sweating, tremor
- Insomnia, nervousness 7
Serious Adverse Effects to Monitor:
- Serotonin syndrome: Occurs in 14-16% of SSRI overdoses. Monitor for tremor, diarrhea, delirium, neuromuscular rigidity, hyperthermia 5. Risk increases when combining with other serotonergic medications.
- Cardiac safety: Therapeutic doses do not affect cardiac conduction or cause orthostasis 7, making fluoxetine significantly safer in overdose compared to tricyclic antidepressants.
Drug Interactions:
When switching to tricyclic antidepressants (TCAs), TCA doses may need reduction and plasma levels monitored due to fluoxetine's long half-life and active metabolite 1.
Comparative Efficacy Context
All second-generation antidepressants show equal effectiveness in treatment-naive patients 5. Medication choice should prioritize patient preferences, adverse effect profiles, cost, and dosing frequency 5. Antidepressants demonstrate greatest efficacy in patients with severe depression 5.
Recent evidence suggests SSRIs are modestly superior to placebo (NNT 7-8), though this represents only a 51% positive trial rate when including unpublished FDA data versus 94% in published literature alone 5.
Practical Algorithm for Initiation
- Confirm indication: MDD, OCD, or bulimia nervosa
- Screen for contraindications: MAOI use, elderly age (consider alternatives)
- Assess for panic disorder: If present, start 5 mg/day and titrate slowly
- Standard initiation:
- MDD adults: 20 mg morning
- MDD pediatric: 10-20 mg morning (weight-based)
- OCD: 20 mg morning (may need 60 mg)
- Bulimia: 60 mg morning (titrate up)
- Adjust for special populations: Reduce dose/frequency for hepatic impairment, elderly, multiple medications
- Set expectations: Full effect requires 4-5 weeks
- Monitor: Adverse effects at 2 weeks, efficacy at 4-6 weeks
- Duration: Minimum 4 months for first episode MDD